Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study

Yazar
Gulmez, Ahmet
AKTAŞ, BURAK YASİN
BAŞOĞLU TÜYLÜ, TUĞBA
Ilhan, Aysegul
Akdeniz, Nadiye
Dogan, Izzet
Kilickap, Sadettin
Karaagac, Mustafa
Avci, Okan
Sen, Erdem
Bilgin, Burak
Sendur, Mehmet Ali Nahit
Yucel, Sebnem
Yalcin, Bulent
Oksuzoglu, Berna
DEMİRKAZIK, AHMET
Demir, Atakan
Dede, Didem Sener
Akinci, Muhammed Bulent
KARATAŞ, FATİH
Deniz, Gulhan Ipek
Taskaynatan, Halil
Sakalar, Teoman
Menevse, Serkan
Kut, Engin
Hizal, Mutlu
Erol, Cihan
Alan, Ozkan
Cinkir, Havva Yesil
TATLI, ALİ MURAT
PAYDAŞ, SEMRA
Yumuk, Fulden
KOCA, SİNAN
Gurbuz, Mustafa
Celik, Emir
Ozyukseler, Deniz Tataroglu
Ayhan, Murat
Üst veri
Tüm öğe kaydını göster
Özet
Background The new second-generation tyrosine kinase inhibitors (TKIs) have superior survival outcome and worse toxicity profile when compared with first-generation TKIs according to the results of clinical trials. However, there are limited studies that investigate the efficacy and safety of the new generation TKIs in real-world patients. Thus, we aimed to compare the efficacy and safety of the afatinib, an irreversible inhibitor of ErbB family receptor, and first-generation TKIs in real-world patients.
Bağlantı
http://hdl.handle.net/20.500.12627/1636
https://doi.org/10.1007/s00432-020-03501-6
Koleksiyonlar